NLRP3 and acute coronary syndrome: Of note, colchicine, a NLRP3 inflammasome inhibitor, has been identified that exerts anti‐inflammatory properties in patients with acute coronary syndrome partly by blocking the activity of monocyte caspase‐1 and thereby inhibiting NLRP3 inflammasome activation.51